Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nautilus Biotechnology, Inc. (NAUT : NSDQ)
 
 • Company Description   
Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE.

Number of Employees: 155

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.33 Daily Weekly Monthly
20 Day Moving Average: 650,152 shares
Shares Outstanding: 126.31 (millions)
Market Capitalization: $167.99 (millions)
Beta: 1.54
52 Week High: $2.92
52 Week Low: $0.62
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 50.69% 47.95%
12 Week 81.94% 69.95%
Year To Date -20.83% -31.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2701 EASTLAKE AVE EAST
-
SEATTLE,WA 98102
USA
ph: 206-333-2001
fax: -
investorrelations@nautilus.bio http://www.nautilus.bio
 
 • General Corporate Information   
Officers
Sujal Patel - Chief Executive Officer; President and Director
Anna Mowry - Chief Financial Officer
Michael Altman - Director
Melissa Epperly - Director
Parag Mallick - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 63909J108
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/25/26
Share - Related Items
Shares Outstanding: 126.31
Most Recent Split Date: (:1)
Beta: 1.54
Market Capitalization: $167.99 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/25/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.99
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 15.38%
vs. Previous Quarter: 8.33%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/25 - -33.35
06/30/25 - -32.53
03/31/25 - -31.87
ROA
09/30/25 - -28.41
06/30/25 - -27.85
03/31/25 - -27.39
Current Ratio
09/30/25 - 14.95
06/30/25 - 18.52
03/31/25 - 17.36
Quick Ratio
09/30/25 - 14.95
06/30/25 - 18.52
03/31/25 - 17.36
Operating Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Book Value
09/30/25 - 1.34
06/30/25 - 1.43
03/31/25 - 1.54
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©